| Wöhrle, Jochen |
NCT05114850: Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve® |
|
|
| Recruiting | N/A | 450 | Europe | | P+F Products + Features GmbH | Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Insufficiency, Heart Failure, Heart Diseases, Heart Valve Diseases | 12/25 | 12/28 | | |
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function |
|
|
| Recruiting | N/A | 1252 | Europe, Canada, US | Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump | Abiomed Inc. | Left Ventricular Dysfunction, Coronary Artery Disease | 03/26 | 10/27 | | |
CLEARANCE, NCT04298723: Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding. |
|
|
| Recruiting | N/A | 530 | Europe | Percutaneous closure of the LAA (Watchman / Watchman FLX) | Jena University Hospital | Atrial Fibrillation (AF), Intracranial Bleed | 06/27 | 06/27 | | |
| Burchardt, Alexander |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy |
|
|
| Active, not recruiting | 3 | 777 | Europe, RoW | Gilteritinib, ASP2215, Midostaurin, Rydapt | Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | 10/25 | 06/33 | | |
| Sinning, Jan-Malte |
AHEAD, NCT03339115: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System |
|
|
| Recruiting | N/A | 30 | Europe | Cardiovalve Transfemoral Mitral Valve | Cardiovalve Ltd., Meditrial Europe Ltd., Meditrial SrL | Mitral Regurgitation, Mitral Valve Disease | 12/24 | 12/29 | | |
NCT06181240: Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE) |
|
|
| Recruiting | N/A | 400 | Europe | Intravascular lithotripsy | Bolt Medical | Coronary Artery Disease, Coronary Artery Calcification | 04/25 | 03/26 | | |
NCT04221815: IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact |
|
|
| Recruiting | N/A | 3100 | Europe, US, RoW | Eagle Eye Platinum digital IVUS catheter with optional SyncVision, Resolute Onyx Drug Eluting Stent, Onyx Frontier Drug Eluting Stent, Onyx TruStar Drug Eluting Stent, Onyx TruCor Drug Eluting Stent | Medstar Health Research Institute | Atherosclerosis | 04/27 | 08/27 | | |
MOTOR, NCT06702527: Optimizing Clinical Outcomes in Patients Undergoing Mitral Transcatheter Edge-to-edge Repair (M-TEER) for Severe Functional Mitral Regurgitation Towards Improved Guideline-directed Medical Therapy |
|
|
| Not yet recruiting | N/A | 100 | Europe | Mitral transcatheter edge-to-edge repair, M-TEER | Institut für Pharmakologie und Präventive Medizin | Mitral Regurgitation Functional, Heart Failure, M-TEER | 09/26 | 09/26 | | |
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function |
|
|
| Recruiting | N/A | 1252 | Europe, Canada, US | Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump | Abiomed Inc. | Left Ventricular Dysfunction, Coronary Artery Disease | 03/26 | 10/27 | | |
| Böning, Andreas |
| Recruiting | 3 | 700 | Europe, Canada, US | Ticagrelor 90 MG, Low-dose aspirin | Weill Medical College of Cornell University, Canadian Institutes of Health Research (CIHR) | Chronic Coronary Disease | 01/27 | 01/31 | | |
AKITA, NCT05126303: Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery |
|
|
| Terminated | 2 | 177 | Europe, Canada, US, RoW | RMC-035, ROSgard, Placebo | Guard Therapeutics AB | Acute Kidney Injury | 04/23 | 07/23 | | |
POINTER, NCT06475274: A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery |
|
|
| Recruiting | 2 | 161 | Europe, Canada | RMC-035, Placebo | Guard Therapeutics AB | Kidney Injury Following Open-Chest Cardiac Surgery | 10/25 | 10/25 | | |
NCT03753607: Renal Venous Flow and Cardiac Surgery-associated Acute Kidney Injury |
|
|
| Completed | N/A | 200 | Europe | No intervention | University of Giessen | Acute Kidney Injury, Cardiorenal Syndrome | 01/22 | 11/23 | | |
HARVITA, NCT05931783: Randomized Comparison of Skeletonized Versus Pedicled Left Internal Thoracic Artery |
|
|
| Recruiting | N/A | 1350 | Europe | skeletonized harvesting technique, pedicled harvesting technique | Medical University Innsbruck | Coronary Artery Disease | 10/28 | 10/31 | | |
| Nef, Holger |
TriCLASP, NCT04614402: Transcatheter Repair of Tricuspid Regurgitation With Edwards PASCAL Transcatheter Valve Repair System |
|
|
| Active, not recruiting | N/A | 300 | Europe | Edwards PASCAL Transcatheter Valve Repair System, Edwards PASCAL Precision Transcatheter Valve Repair System | Edwards Lifesciences | Tricuspid Valve Insufficiency | 04/23 | 03/28 | | |
| Active, not recruiting | N/A | 2001 | Europe | QFR-based diagnostic strategy, FFR-based diagnostic strategy | Aarhus University Hospital Skejby, Medis Medical Imaging Systems | Coronary Artery Disease | 07/23 | 12/25 | | |
| Recruiting | N/A | 500 | Europe | IASD Implant | Corvia Medical | Heart Failure | 07/26 | 07/28 | | |
NCT06181240: Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE) |
|
|
| Recruiting | N/A | 400 | Europe | Intravascular lithotripsy | Bolt Medical | Coronary Artery Disease, Coronary Artery Calcification | 04/25 | 03/26 | | |
NCT02710435: REDUCER-I: An Observational Study of the Neovasc Reducer™ System |
|
|
| Active, not recruiting | N/A | 400 | Europe | Reducer System, Reducer | Neovasc Inc., Shockwave Medical, Inc. | Angina Pectoris, Angina Pectoris, Stable, Chronic Stable Angina | 11/23 | 12/28 | | |
| Recruiting | N/A | 1000 | Europe | Edwards PASCAL Transcatheter Valve Repair System and Edwards PASCAL Precision Transcatheter Valve Repair System | Edwards Lifesciences | Mitral Regurgitation, Mitral Insufficiency | 12/25 | 03/31 | | |
| Recruiting | N/A | 1247 | Europe, Canada, US | Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System | Edwards Lifesciences | Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation | 01/25 | 04/30 | | |
NCT04221815: IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact |
|
|
| Recruiting | N/A | 3100 | Europe, US, RoW | Eagle Eye Platinum digital IVUS catheter with optional SyncVision, Resolute Onyx Drug Eluting Stent, Onyx Frontier Drug Eluting Stent, Onyx TruStar Drug Eluting Stent, Onyx TruCor Drug Eluting Stent | Medstar Health Research Institute | Atherosclerosis | 04/27 | 08/27 | | |
DOUBLE-CHOICE, NCT05036018: RanDOmized stUdy Comparing Both Latest Generation Self-Expanding Valves and a Minimalist approaCH vs. Standard Of Care In transCathEter Aortic Valve Implantation |
|
|
| Active, not recruiting | N/A | 836 | Europe | ACURATE neo2, minimalist approach, CoreValve Evolut Pro and Pro+, Standard of care | Leipzig Heart Science gGmbH, Heart Center Leipzig - University Hospital | Aortic Valve Stenosis | 02/25 | 12/33 | | |
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function |
|
|
| Recruiting | N/A | 1252 | Europe, Canada, US | Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump | Abiomed Inc. | Left Ventricular Dysfunction, Coronary Artery Disease | 03/26 | 10/27 | | |
| Recruiting | N/A | 360 | Europe | Transcatheter tricuspid valve treatment (TTVT) | LMU Klinikum, Heart and Diabetes Center North Rhine-Westphalia, University Medical Center Mainz, Heart Center Leipzig - University Hospital, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), University of Leipzig | Heart Failure Attributable to Severe Tricuspid Regurgitation | 03/26 | 03/27 | | |
| Recruiting | N/A | 1054 | Europe | measurement of FFR, measurement of Pd/Pa | Helios Health Institute GmbH, Heart Center Leipzig - University Hospital | Coronary Artery Disease, Coronary Artery Stenoses | 05/26 | 11/26 | | |
| Nordbeck, Peter |
| Terminated | 3 | 17 | Europe, Canada | REPLAGAL, SHP675 | Shire | Fabry Disease | 12/22 | 12/22 | | |
| Active, not recruiting | 1/2 | 34 | Europe, Canada, US, RoW | ST-920 | Sangamo Therapeutics | Fabry Disease | 04/25 | 09/25 | | |
AIM-ICD, NCT04264455: Evaluation of Long-term Incidence of Ventricular Arrhythmias in Patients With Acute Myocarditis |
|
|
| Recruiting | N/A | 34 | Europe | Biomonitor, Life Vest, Implantable Cardioverter-Defibrillator (ICD) | Wuerzburg University Hospital, MVZ Leopoldina GmbH, Brandenburg Medical School Theodor Fontane, Hannover Medical School | Myocarditis Acute, Ventricular Arrythmia | 12/22 | 12/23 | | |
NCT03022851: The Prophet Trial -Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Patients With Pulmonary Hypertension |
|
|
| Recruiting | N/A | 30 | Europe, RoW | Occlutech AFR Device | Occlutech International AB | Pulmonary Hypertension | 02/23 | 12/23 | | |
| Completed | N/A | 360 | Europe | Conventional circulatory support, Conventional circulatory support will be employed according to enrolling sites usual management., Impella CP, Impella CP, Abiomed | Odense University Hospital, Aarhus University Hospital Skejby, Hannover Medical School, University Hospital, Bonn, Jena University Hospital, University Hospital Dresden, Heinrich-Heine University, Duesseldorf, Universitätsklinikum Hamburg-Eppendorf, Charite University, Berlin, Germany, Royal Brompton & Harefield NHS Foundation Trust, Wuerzburg University Hospital, Rigshospitalet, Denmark | Cardiogenic Shock Acute, Acute Myocardial Infarction | 07/23 | 04/24 | | |
| Recruiting | N/A | 3000 | Europe | Time (outcome) | Wuerzburg University Hospital | Heart Failure, Chronic Heart Failure, Chronic Heart Disease | 12/23 | 12/23 | | |
| Recruiting | N/A | 30 | Europe | | Wuerzburg University Hospital, Charite University, Berlin, Germany, University Hospital Muenster, Health Care Center Dr. Markus Cybulla, Muellheim | Rare Diseases, Fabry Disease, Adherence, Medication, Quality of Life | 12/23 | 12/23 | | |
| Recruiting | N/A | 750 | Europe, Canada, US, RoW | Corvia Atrial Shunt System / IASD System II, Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) | Corvia Medical | Heart Failure, Heart Failure, Diastolic | 05/25 | 03/31 | | |
| Active, not recruiting | N/A | 965 | Europe, US | ommitence of defibrillation testing | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Boston Scientific Corporation | Ventricular Arrythmia | 04/25 | 07/25 | | |
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function |
|
|
| Recruiting | N/A | 1252 | Europe, Canada, US | Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump | Abiomed Inc. | Left Ventricular Dysfunction, Coronary Artery Disease | 03/26 | 10/27 | | |
GoPEG, NCT06095713: German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa |
|
|
| Recruiting | N/A | 60 | Europe | Pegunigalsidase-alfa | Westfälische Wilhelms-Universität Münster, Chiesi GmbH | Fabry Disease | 03/26 | 03/26 | | |
| Recruiting | N/A | 650 | Europe | | Wuerzburg University Hospital, Competence Network Heart Failure, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), St George's, University of London | Rare Diseases, Fabry Disease, Fabry Disease, Cardiac Variant, Hypertrophic Cardiomyopathy | 03/32 | 03/32 | | |
| Gall, Henning |
| Completed | 2 | 108 | Europe, Canada, US, RoW | rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo | Altavant Sciences GmbH | Pulmonary Arterial Hypertension | 06/23 | 08/23 | | |
PEGASUS, NCT03051763: The Effects of Commercial Air Travel on Patients Suffering From Pulmonary Hypertension |
|
|
| Recruiting | N/A | 1000 | Europe | | University of Giessen, Universitätsklinikum Hamburg-Eppendorf, DRK Kliniken Berlin Köpenick, Berlin, Germany, University Hospital, Zürich, University Hospital Carl Gustav Carus | Pulmonary Hypertension, Pulmonary Arterial Hypertension | 12/21 | 05/22 | | |
NCT03402971: The Right Heart During and After Pregnancy - an Echocardiographic Study |
|
|
| Recruiting | N/A | 1000 | Europe | echocardiography, parallel EKG | Gero Bunniger | Pregnancy Related | 11/23 | 11/24 | | |
| Recruiting | N/A | 1500 | Europe, US, RoW | assessment of pulmonary hemodynamics during exercise by right heart catheterization | Medical University of Graz, European Respiratory Society | Pulmonary Circulation Diseases | 12/29 | 12/29 | | |
| Enrolling by invitation | N/A | 500 | Europe | Capnography | University of Giessen | Hypertension, Pulmonary, Hypertension;Pulmonary;Primary, Chronic Thromboembolic Pulmonary Hypertension, Vascular Diseases, Lung Diseases | 01/30 | 01/35 | | |
NCT04145024: Giessen Pulmonary Hypertension Registry and Biobank |
|
|
| Recruiting | N/A | 10000 | Europe | | University of Giessen | Pulmonary Hypertension | 07/35 | 01/36 | | |
| Recruiting | N/A | 40000 | Europe | | University of Giessen, Imperial College London, Johns Hopkins University, Stanford University, University of Sheffield, University of Pittsburgh, University of Pavia, Hospital de Niños de la Santísima Trinidad, Academy of Medical Sciences of Ukraine, The Methodist Hospital Research Institute, Vanderbilt University Medical Center, Mayo Clinic, National and Kapodistrian University of Athens, Aristotle University Of Thessaloniki, University Hospital of Targu Mures, Romania, University Hospital Heidelberg, Milpark Hospital | Pulmonary Hypertension, Global Health | 01/50 | 01/55 | | |
| Wehler, Thomas |
NCT04413201: AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC |
|
|
| Active, not recruiting | 4 | 34 | Europe | Afatinib, Osimertinib | Michael Hopp, Boehringer Ingelheim | Non-squamous NSCLC | 06/24 | 06/24 | | |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
| Recruiting | 2 | 105 | Europe | Durvalumab, IMFINZI®, standard of care | Michael Hopp, AstraZeneca | Small Cell Lung Cancer Limited Stage | 09/23 | 09/23 | | |
CaboRISE, NCT04522908: Dose Escalation Study of Cabozantinib for Advanced HCC Patients with Preserved Liver Function |
|
|
| Completed | 2 | 40 | Europe | Cabozantinib Oral Tablet, CABOMETYX | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Johann Wolfgang Goethe University Hospital, Prof. Dr. med. Trojan | Hepatocellular Carcinoma (HCC), Second Line Treatment | 10/24 | 10/24 | | |
| Active, not recruiting | 2 | 36 | Europe | Copanlisib, Aliqopa, Rituximab, Truxima | Christian Buske, University of Ulm, Optimapharm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Celltrion Healthcare Co., LTD, Bayer | Marginal Zone Lymphoma | 06/24 | 12/29 | | |
| Completed | 2 | 92 | Europe | Carboplatin AUC 5, Cisplatin 75 mg/m2, Pemetrexed 500 mg/m2, Nivolumab Injection, Opdivo | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Bristol-Myers Squibb, Thoraxklinik Heidelberg gGmbH - Universitätsklinikum Heidelberg | Pleural Mesothelioma Malignant | 01/25 | 01/25 | | |
NCT06680622: Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy |
|
|
| Not yet recruiting | 2 | 126 | Europe | bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Amgen, Johannes Gutenberg University Mainz, Technical University of Munich | Metastatic Gastro-esophageal Adenocarcinoma | 09/27 | 03/28 | | |
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination |
|
|
| Recruiting | 1/2 | 576 | Europe, US, RoW | MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy | Merus N.V. | Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | 03/26 | 03/27 | | |
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) |
|
|
| Active, not recruiting | 1/2 | 61 | Europe, Japan, US, RoW | M1774, Tuvusertib, Cemiplimab | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Non-Small Cell Lung Cancer | 05/25 | 02/26 | | |
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project |
|
|
| Recruiting | N/A | 50000 | Europe | | University of Ulm | Acute Myeloid Leukemia (AML), MDS/AML | 12/44 | 12/44 | | |
NCT04896931: New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a Permanent Platform Including All Kind of Biliary Tract Cancers (BTC) |
|
|
| Recruiting | N/A | 200 | Europe | | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Biliary Tract Cancer, Neoadjuvant, Adjuvant and 1st Line | 09/29 | 09/29 | | |
| Braun, Tobias |
| Terminated | N/A | 40 | Europe | Daniels Water Swallow Test, Flexible Endoscopic Evaluation of Swallowing, FEES | University of Giessen | Stroke, Acute | 02/23 | 02/23 | | |
| Recruiting | N/A | 200 | Europe | FEES (flexible endoscopic evaluation of swallowing), Sensitivity threshold, Taste-/smell-test, Neuropsychological testing | University of Giessen | Dysphagia, Stroke | 02/25 | 12/26 | | |
NCT04866251: Prevalence of Gag Reflex in Healthy Persons and Across Different Patient Groups and Its Relevance in Dysphagia Screening |
|
|
| Recruiting | N/A | 700 | Europe | Gag reflex test; assessment of Mallampati Score | University of Giessen | Neurological Diseases or Conditions | 07/24 | 07/24 | | |
| Recruiting | N/A | 570 | Europe | BJH-SDS Screenint Test, Flexible Endoscopic Evaluation of Swallowing, FEES | University of Giessen | Dysphagia, Stroke, Acute | 04/26 | 05/26 | | |
| Recruiting | N/A | 2000 | Europe | | University of Giessen | Stroke, Acute, Comorbidities and Coexisting Conditions, Critical Care | 12/26 | 12/27 | | |
| Samra, Maisun Abu |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project |
|
|
| Recruiting | N/A | 50000 | Europe | | University of Ulm | Acute Myeloid Leukemia (AML), MDS/AML | 12/44 | 12/44 | | |
| Schroers, Roland |
| Recruiting | 4 | 50 | Europe | Upfront autologous HSCT | UMC Utrecht, ZonMw: The Netherlands Organisation for Health Research and Development, Boehringer Ingelheim, Miltenyi Biotec, Inc. | Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma, Scleroderma, Diffuse, Autologous Stem Cell Transplantation, Cyclophosphamide, Mycophenolate Mofetil, Treatment Strategy | 10/27 | 10/30 | | |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy |
|
|
| Active, not recruiting | 3 | 777 | Europe, RoW | Gilteritinib, ASP2215, Midostaurin, Rydapt | Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | 10/25 | 06/33 | | |
NCT04628026: Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 |
|
|
| Recruiting | 3 | 650 | Europe | Venetoclax, Placebo, Standard chemotherapy, Autologous stem cell transplantation, Allogeneic stem cell transplantation | University of Ulm, Stichting Hemato-Oncologie voor Volwassenen Nederland | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 02/25 | 02/31 | | |
| Active, not recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/29 | | |
R-Pola-Glo, NCT05798156: Rituximab in Combination with Glofitamab and Polatuzumab Vedotin in Patients with Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP |
|
|
| Recruiting | 2 | 125 | Europe | Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche | Lymphoma, Large B-Cell, Diffuse | 04/25 | 09/28 | | |
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project |
|
|
| Recruiting | N/A | 50000 | Europe | | University of Ulm | Acute Myeloid Leukemia (AML), MDS/AML | 12/44 | 12/44 | | |
| Eul, Bastian |
NCT04318938: Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping |
|
|
| Active, not recruiting | 2 | 118 | Europe | Brigatinib, Study treatment, Tyrosine kinase inhibitor | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, Takeda | NSCLC | 01/26 | 01/26 | | |
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) |
|
|
| Active, not recruiting | 1/2 | 61 | Europe, Japan, US, RoW | M1774, Tuvusertib, Cemiplimab | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Non-Small Cell Lung Cancer | 05/25 | 02/26 | | |
| Recruiting | N/A | 500 | Europe | All lung cancer patients. | University of Giessen | Pulmonary Hypertension Due to Lung Diseases and Hypoxia | 01/26 | 01/40 | | |
| Aßmus, Birgit |
| Not yet recruiting | N/A | 1057 | Europe | Interdisciplinary decision-making for perioperative care | University of Giessen, Deutsche Luft und Raumfahrt | Heart Failure | 08/26 | 03/27 | | |
NCT04398654: Pulmonary Artery Sensor System Pressure Monitoring to Improve Heart Failure (HF) Outcomes |
|
|
| Recruiting | N/A | 554 | Europe | CardioMEMSTM HF sensor - pulmonary artery pressure measurement | IHF GmbH - Institut für Herzinfarktforschung | Heart Failure | 06/26 | 12/26 | | |
| Kalder, Johannes |
| Active, not recruiting | N/A | 260 | Europe, Canada, US, RoW | JETi Peripheral Thrombectomy System | Abbott Medical Devices | Peripheral Artery Thrombosis, Peripheral Venous Thrombosis | 08/24 | 08/25 | | |
NCT05923749: A RCT Evaluating the Clinical Benefit of a Silver Dressing in the Treatment of Venous Leg Ulcers |
|
|
| Recruiting | N/A | 178 | Europe, US | Biatain Ag, Cutimed Siltec Sorbact | Coloplast A/S | Wound Heal | 10/25 | 10/25 | | |
| Landt, Martin |
DOUBLE-CHOICE, NCT05036018: RanDOmized stUdy Comparing Both Latest Generation Self-Expanding Valves and a Minimalist approaCH vs. Standard Of Care In transCathEter Aortic Valve Implantation |
|
|
| Active, not recruiting | N/A | 836 | Europe | ACURATE neo2, minimalist approach, CoreValve Evolut Pro and Pro+, Standard of care | Leipzig Heart Science gGmbH, Heart Center Leipzig - University Hospital | Aortic Valve Stenosis | 02/25 | 12/33 | | |
